C-reactive protein was found to be useful for predicting outcomes, such as early death and bleeding in patients with venous thromboembolism.7,8 Similarly, high CRP is associated with recurrence risk of venous thromboembolism in cancer patients after discontinuation of anticoagulation with no effect on mortality.8 Fibrin D-dimer predicts cancer-associated thrombosis,9 but there is insufficient evidence regarding its relevance in other patient populations. This evidence concerns the gene CRP and venous thromboembolism.